ANGLE plc, a liquid biopsy company, has published a study demonstrating the potential of its Parsortix system in characterizing circulating tumor cells (CTCs) in Head and Neck Squamous Cell Carcinoma (HNSCC). The study, conducted by researchers at the University of Birmingham, used mass cytometry to comprehensively analyze CTCs captured by the Parsortix system. The technology allowed for the simultaneous analysis of multiple proteins on and within individual CTCs, providing a deep understanding of their phenotypic status and diversity. The study revealed a correlation between epithelial to mesenchymal transition and immune checkpoint protein expression in HNSCC. The findings offer new insight into the molecular heterogeneity of HNSCC and could support the development of personalized treatment strategies and real-time monitoring of treatment response. The study is published in the British Journal of Cancer.